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Abstract Recent studies have shown that both CDX2 and
Hepatocyte antigen (Hep) are detected in different types of
cancer and associated with clinical prognosis. However,
fever studies have examined gallbladder cancer specimens,
and little is known about the clinicopathological signifi-
cance of both CDX2 and Hep expression in gallbladder
adenocarcinomas. In present study, we examined the
expression frequencies of CDX2 and Hepatocyte antigen
(Hep), and explored their clinicopathologic significances in
gallbladder adenocarcinoma. Immunohistochemistry was
used to detect and compare the frequencies of CDX2 and
Hep expression in 108 samples of gallbladder adenocarci-
noma, 46 peri-tumor tissues and 35 chronic cholecystitis.
The expression frequencies for CDX2 and Hep were 49/
108 (45.4%) and 45/108 (41.7%) in gallbladder carcinoma;
13/46 (28.3%) and 11/46 (23.9) in peri-tumor tissues; 5/35
(14.3%) and 2/35 (5.7%) in chronic cholecystitis. The
positive staining of CDX2 or Hep in gallbladder adenocar-
cinoma was significantly higher than that in peritumoral
tissues (both, P<0.05), and chronic cholecystits (both, P<
0.01). The expression of CDX2 or Hep was negatively
correlated to grade of differentiation, tumor size and lymph
node metastasis (P<0.01 or P<0.05). Elevated expression
frequency of CDX2 or Hep was associated with increased
overall survival (P=0.003 or P=0.002). Multivariate Cox
regression analysis showed that CDX2 (P=0.014) or Hep
(P=0.026) expression was an independent prognostic
predictor in gallbladder adenocarcinoma. CDX2 and Hep
might function as important biological markers in the
development and prognosis of gallbladder adenocarcinoma.
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Abbreviations
CDX2 Caudal-related homeobox transcription factor
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Hep Par 1 Hepatocyte paraffin 1 monoclonal antibody
Introduction
Gallbladder cancer is often a terminal malignancy
occurring predominantly in the elderly women. It
accounts for nearly two-thirds of the biliary tract
cancers, making it the most common primary biliary
cancer and the fifth most common cancer of the gastro-
intestineal tract [1, 2]. More than 85% of gallbladder
cancers belong to adenocarcinomas often well or moder-
ately differentiated, and the rest approximately 15% are
squamous, adenosquamous or undifferentiated carcinoma.
To date surgery is the only potentially curative modality
for patients with gallbladder cancer, however, more than
70% of cases is unresectable owing to local invasion and
metastasis. A better understanding of pathogenesis and
clinicopathological charateristics of gallbladder cancer
may provide insights for early diagnosis and treatment
improvement for this deadly disease.
Caudal type homeobox transcription factor CDX2 is
mostly expressed in small and large intestinal epithelial
Q.-L. Li:Z.-L. Yang (*):J.-Q. Liu:X.-Y. Miao
Research Laboratory of Hepatobiliary Diseases,
The Second Xiangya Hospital of Central South University,
139 Middle Renmin Road,
Changsha, Hunan 410011, China
e-mail: zhulin.yang@yahoo.com
Pathol. Oncol. Res. (2011) 17:561–568
DOI 10.1007/s12253-010-9346-7cells and plays an essential role in regulating proliferation
and differentiation of the intestinal epithelium [3, 4]. CDX2
expression has been considered as a sensitive marker of
intestinal metaplasia in the esophagus [5, 6] and stomach
[7, 8]. Recent studies have shown that CDX2 expression is
also detected in intestinal-type gastric carcinoma, esopha-
geal carcinoma, and other malignancies such as cholangio-
carcinoma and intraductal papillary neoplasia of the liver
[9–14]. In gallbladder, CDX2 expression is not seen in the
normal tissue, however it has been detected in the intestinal
metaplasia mucosa in cholelithiasis [15] ,a n da l s oi n
adenocarcinoma [16, 17]. Few studies reported the rela-
tionship between CDX2 expression and prognosis of
gallbladder adenocarcinoma [16]. The clinical and patho-
logical significance of CDX expression in gallbladder
adenocarcinoma remains to be further elucidated.
Hepatocyte antigen (Hep) is detected by Hep Par 1, a
monoclonal antibody developed from Hepatic tissue from a
failedliveallograftandconsideredtobespecificfornormaland
neoplastic Hepatocytes. Therefore, Hep has emerged as a
diagnostic marker in surgical histopathology to distinguish
Hepatocellular carcinoma(HCC)from livermetastases of other
carcinomas[18, 19]. However subsequent studies has revealed
that Hep expression has been detected in cholangiocarcinomas
[20, 21], gallbladder carcinomas [22, 23], gastric carcinomas
and others [21–25]. To our knowledge, the clinicopathological
significance of Hepatocyte antigen expression in gallbladder
adenocarcinoma has not been reported.
In the present study, we examined the expression
frequency of CDX2 and Hepatocyte antigen in 108 speci-
mens of gallbladder adenocarcinoma, 46 of peri-tumor
tissues and 35 of chronic cholecystitis by means of
immunohistochemistry with attempt to better understand
the reasons for CDX2 and Hep expression in lesions of
gallbladder and its clinicopathological implications.
Materials and Methods
Specimens and Clinicopathologic Materials
Gallbladder carcinoma resection specimens were collected
from 108 cases hospitalized in the Second and First
Xiangya Hospital of Central South University, and People’s
Hospital of Hunan Province (Changsha, China) from June
1996 through June 2006. Of the 108 cases with gallbladder
carcinoma, 31 was male (28.7%) and 77 was female
(71.3%). Ages of patients were from 35 to 70 years old
with an average 52.6±11.2. The pathological types of these
cases were all adenocarcinoma, including 9 cases (8.2%) of
adenomatous canceration, 29 cases (26.9%) of well-
differentiated adenocarcinoma, 29 cases (26.9%) of
moderately-differentiated adenocarcinoma, 30 cases
(27.8%) of poorly-differentiated adenocarcinoma, and 11
cases (10.2%) of mucinous adenocarcinomas. There were
59 cases (54.6%) with peri-gallbladder infiltrations, 59
(54.6%) with regional lymph node metastasis, and 58
(57.3%) with gallbladder cancer complicated with gall-
stones. There were 34 cases (31.5%) with radical resection,
48 (44.4%) with palliative operation, and 26 (24.1%) with
no operation because of distant metastasis. In 46 selected
peritumoral tissues (away from tumor ≥3 mm) from some
of above patients, 10 were normal, 10 were mild atypical
hyperplasia, 12 were middle atypical hyperplasia, and 14
were severe atypical hyperplasia. And another 35 cases of
chronic cholecystitis specimens (15 cases of simple chronic
cholecystitis and 20 cases of chronic cholecystitis compli-
cated with gallstones) were also selected as control, in
which there were 11 cases of normal tissues, 12 cases of
mild atypical hyperplasia, 7 cases of middle atypical
hyperplasia and 5 cases of severe atypical hyperplasia. All
these specimens were fixed by 4% formaldehyde, followed
by conventional paraffin-embedded sectioning.
Immunohistochemical Staining
Mouse anti-human CDX2 and Hep Par 1 monoclonal
antibodies and EnVision™ Detection Kit were from Dako
Laboratories, California, USA. The staining of CDX2 and
Hep were carried out according to the manufacture’s
protocol (ChemMate™ EnVison +/HRP/DAB, Rabbit/
Mouse Two Step Staining Method). Briefly, the sections
were deparaffined and incubated with peroxidase inhibitor
(3% H2O2) in dark for 15 min, followed by EDTA-
trypsinase digestion liquid (0.125%, pH 9.0) for 15 min,
then soaked with PBS liquid (pH7.4) three times with each
for 5 min. The pretreated sections were then incubated with
mouse anti-CDX2 or -Hep Par 1 for 60 min under room
temperature. After three rinses with PBS, solution A was
added to the sections, and incubated for 30 min at room
temperature. Substrate DAB was added and followed by
hematoxylin counter-staining. The Slides were dehydrated
with different concentrations (70%–100%) of alcohol, and
soaked in xylene for three times with each 5 min. and
finally mounted with neutral balsam. The readouts of
CDX2 or Hep staining were considered as positive when
more than 20% of the tumor cells were stained, otherwise
as negative. The positive controls were the positive sections
that provided by Dako, and the negative controls were the
0.01 mol/L PBS liquid (pH7.4) (substitute the first
antibody).
Statistically Analysis
The SPSS13.0 program was used for calculation of inter-
relationships between the analyzed CDX2 or Hep and
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Fisher’s exact probability test was also used for analyzing
statistical association between the two independent sample
groups. The results were considered to be significant when
the P value were less than 0.05. Disease specific overall
survival analyses were determined and compared using the
Kaplan-Meier method and the log-rank test. For multivar-
iate analysis the Cox regression method was performed.
95% confidence intervals were used overall.
Results
Expressions of CDX2 and Hep in Benign and Malignant
Lesions of Gallbladder
We examined expression of CDX2 and Hep by immunos-
taining in 108 cases of gallbladder adenocarcinoma, 46
Fig. 1 Immunohistochemical staining of CDX2 in gallbladder
adenocarcinoma and peritumoral tissue (×200). a CDX2 positive
staining was observed in nuclei of a representative moderately-
differentiated gallbladder adenocarcinoma. b CDX2 expression was
located in nuclei of a representative peritumoral tissue with severely-
atypical hyperplasia
Fig. 2 Expression of Hep in gallbladder adenocarcinoma and chronic
cholecystitis (×200). a Positive staining of Hep was seen in
cytoplasms in a representative well-differentiated adenocarcinoma. b
Positive expression of Hep was detected in cytoplasms of a
representative chronic cholecystitis with moderately-atypical hyper-
plasia. c Typical Hep staining of hepatocytes in a liver section
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cholecystitis. Positive CDX2 staining was seen in the nuclei
of carcinoma cells, as shown in Fig. 1. Hep staining was
observed in the cytoplasm and/or cell membrane with
brown-yellow granules as shown in Fig. 2 (a and b). For
comparison, a typical Hep positive staining of hepatocytes
from a liver section was shown in Fig. 2c. Overall, of the
108 cases of gallbladder adenocarcinomas, expression of
CDX2 and Hep was detected in 49 (45.4%) and 45 (41.7%)
cases, respectively. In the 46 cases of pericancerous tissues,
CDX2 and Hep were positive in 13 (28.3%) and 11
(23.9%) cases, respectively. However, in the 35 cases of
chronic cholecystitis, CDX2 and Hep stains were positive
in 5 (14.3%) and 2 (5.7%) cases. Statistically, the positive
rates of CDX2 and Hep in gallbladder adenocarcinoma
were significantly higher than those in peritumoral tissues
(χ
2=3.93, P<0.05 and χ
2=4.39, P<0.05 respectively) and
chronic cholecystitis (χ
2=10.87, P<0.01 and χ
2=15.49,
P<0.01 respectively). In addition, moderate to severe
atypical hyperplasia were observed in all CDX2 and Hep-
positive cases of peritumoral tissues and chronic cholecystitis
epitheliums. Some of the benign lesions and gallbladder
adenocarcinoma showed morphological evidences of intesti-
nal metaplasia, such as existence of goblet cells, secretion of
mucus, and high columnar cancer cells.
Expressions of CDX2 and Hep and Their Correlation
With Clinicopathologic Parameters of Gallbladder
Adenocarcinoma
We further analyzed whether expression of CDX2 and
Hep was correlated with the clinical and pathological
features of gallbladder adenocarcinoma. As shown in
Table 1, the frequencies of CDX2 and Hep expression in
the cases with adenomatous canceration, maximal
diameter of mass <2 cm, and no-metastasis of lymph
node were significantly higher than those in the ones
characterized by poorly-differentiated adenocarcinoma,
maximal diameter of mass ≥2 cm, and metastasis of
lymph node (P<0.05 or P<0.01). The positive rate of
CDX2 in cases with no-invasive regional tissues was
significantly higher than that in cases with invasive
regional tissues (P<0.01). 37 cases were Hep-positive in
the 49 CDX2-positive cases, and highly consistency in
CDX2 and Hep expression was found in gallbladder
adenocarcinoma (χ
2=42.27, P<0.01).
Table 1 Expressions of CDX2 and Hep and their correlation with clinicopathologic parameters of gallbladder adenocarcinoma
Group n CDX2+ (%) P-value (χ
2-test) Hep Par 1 + (%) P-value (χ
2-test)
Sex
Male 31 14(45.2) >0.05 14(45.2) >0.05
Female 77 35(45.5) 31(40.3)
Age
≤45 24 11(45.8) >0.05 10(41.7) >0.05
>45 84 38(45.2) 35(41.7)
Pathologic type
Adenomatous canceration 9 8(88.9) <0.01 7(77.8) <0.05
Well-differentiated 29 16(55.2) 16(55.2)
Moderately-differentiated 29 13(44.8)
a 12(41.4)
a
Poorly-differentiated 30 7(23.3)
b,c 6(20.0)
b,c
Mucinous adenocarcinoma 11 5(45.5) 4(36.4)
Tumor diameter
<2.0 cm 31 21(67.7) <0.01 18(58.1) <0.05
≥2.0 cm 77 28(36.4) 27(35.1)
Lymph node metastasis
No 49 31(63.2) <0.01 26(53.1) <0.05
Yes 59 18(30.1) 19(32.2)
Surrounding tissue invasion
No 49 30(61.2) <0.01 24(49.0) >0.05
Yes 59 19(32.2) 21(35.6)
Gallstones
No 50 20(40.0) >0.05 21(42.0) >0.05
Yes 58 29(50.0) 24(41.3)
aP<0.05 and
bP<0.01 when compared to adenomatous canceration;
cP<0.05 when compared to well-differentiation adenocarcinoma.
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Specific Overall Survival
After surgical resection, only 67 out of 108 patients were
able to be followed up via phone or mail surveys. Of the 67
cases with follow-up, 20 cases had over 1 year survival, and
47 died within 1 year after surgery, with a mean survival
time of 9.6±5.2 months. 36 of the 67 (53.7%) patients had
positive staining of CDX2 and 35 (52.2%) had Hep positive
staining. The relevance of positive CDX2 and Hep
expression to patients’ survival was examined by univariate
Kaplan-Meier survival analysis. Overall survival was
positive association with increased expression frequencies
of CDX2 (P=0.003) (Fig. 3a) and Hep (P=0.020) (Fig. 3b).
The relevance of overall survival and other clinicopatho-
logical characteristics were also assessed by univariate
analysis which showed that the overall survival was
associated with tumor pathological type(P=0.031), tumor
diameter(P=0.003), lymph node metastasis (P=0.005) and
surrounding tissue invasion (P=0.002). All factors that
showed significant association in the univariate Kaplan-
Meier analysis were subsequently subject to multivariate
Cox regression survival analysis, which indicated that
lymph node metstasis and surrounding tissue invasion were
the most significant predictors of short overall survival
followed by CDX2 and Hep expression (Table 2).
Discussion
Under normal conditions, CDX2 expression is intestine-
specific and plays an important role in the regulation of cell
proliferation and differentiation in the embryo and gut.
Recent studies demonstrated that ectopic CDX2 expression
has been observed in intestinal metaplasia and carcinoma of
the stomach, it might be related to gastric mucosa
transformation from gastric to intestinal phenotype, and
gastric carcinogenesis [9, 10, 13]. CDX2 expression was
not detected in normal gallbladder mucosa [17]. We
reported here that ectopic CDX2 expression was detected
in 49/108 (45.4%) of gallbladder adenocarcinoma. In the
108 cases of gallbladder carcinoma, there was no differen-
tial frequency of CDX2 expression in different sex groups,
age, and with or without gallstones. However, we observed
there was a trend of increasing expression frequency of
CDX2 in benign lesions and CDX2 was strongly relevant
to grades of tumor differentiation.
CDX2 expression has been considered as one of the
good prognostic markers in patients with gastric carcinoma
[13, 26, 27], pancreatic tumor [28], and carcinoma of the
ampulla of Vater [29]. Few studies have examined CDX2
expression in gallbladder cancer specimens. Wu et al.
reported that CDX2 expression was detected in 25 (36.8%)
of 68 gallbladder carcinomas, and was closely related to
histological differenation grades, i.e., in the tubular type
gallbladder carcinomas, significantly higher expression in
well-differentiated type than the moderately and poorly
differentiated types, indicating that ectopic expression of
CDX2 is an early event in gallbladder carcinomas.
However, whether CDX2 can be a prognostic factor
remained unclear in their study due to limited case number
obtained [17]. Jinawath et al. have found that CDX2
expression was observed in 22 (37.3%) of 59 cholangio-
carcinoma cases, and correlated with MUC2 expression.
Fig. 3 Kaplan-Meier plots for overall survival in 67 patients with
gallbladder adenocarcinoma surgery in relation to CDX2 and Hep
expression. a Positive or increased CDX2 expression was associated
with increased over survival (P=0.003, log rank test). b Hep
expression was also related to increased overall survival (P=0.02,
log rank test)
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than tubular-type cholangiocarcinoma [14]. Additionally,
Hong et al. have shown that CDX2 was detected in 72
(37.3%) out of 193 extraHepatic bile duct carcinomas and
correlated with histologic subtypes, and more frequently in
tumors with papillary growth and no vascular invasion.
They further concluded that Patients with CDX2+/MUC2+
tumors had significantly better overall survival in univariate
but not multivariate analysis than patients with other tumors
[30]. Chang et al. demonstrated that 27/164 (16.46%)
patients with biliary tract carcinoma expressed CDX2, and
the frequency of CDX2 expression was much higher in
gallbladder carcinoma (12/41, 29.3%) and extrahepatic
cholangiocarcinoma (22.45%) than in the intrahepatic
cholangiocarcinoma [16]. By univariate and multivariate
analyses, the expression of CDX2 was associated with a
significant survival advantage; CDX2 and tumor stage were
independent prognostic factor in patients with biliary tract
carcinomas [16]. In our study, CDX2 expression was
associated with tumor differentiation stages, it was found
much higher in benign lesions, i.e. adenomous canceration
and well-differentiated types, than the poor-differentiated
type. Additionally, CDX2 expression was associated with
better over survival patients with gallbladder carcinomas,
and multivariate Cox regression analysis showed that
CDX2 was an independent predictor of survival in addition
to lymph node metstasis and surrounding tissue invasion
after resection of gallbladder tumor.
Hep is a component of the membrane of hepaticcellular
mitochondrial. The positive rates of Hep in normal hepatic
cells and cells of chronic hepatic diseases were 100%, and
the positive rate of Hep in hepatocellular carcinoma was
above 90%, especially that in well-differentiated Hepato-
cellular carcinoma was nearly 100%, so Hep was regarded
as an important marker for diagnosis of hepatocellular
carcinoma and differential diagnosis between hepatocellular
carcinoma and metastatic carcinoma of liver, and positive
cases had better prognosis than negative cases [8]. Recent
studies have found that Hep had high expression in many
other malignant tumors, such as intestinal gastric cancer
and esophagus adenocarcinoma with intestinal metaplasia,
and Hep was regarded as a specific marker reflecting
intestinal metaplasia of gastric mucosa; malignant tumors
with higher Hep expression had better prognosis, and Hep
was regarded as a objective biological marker reflecting the
prognosis of malignant tumors [13, 18, 24, 31–33]. To our
knowledge, quite few literatures have reported the expres-
sion of Hep in gallbladder carcinoma, in nomoral condition
there is no Hep expression detected in gallbladder tissue. In
gallbladder adenocarcinomas, the Hep expression rate from
0 to 100% have been reported [20–23]. When Leong et al.
used Hep par 1 to distinct hepatocellular carcinoma from
cholangiocarcinoma, combined tumors and metastatic car-
cinoma, they did not detect Hep expression in 2 cases of
metastic gallbladder adenocarcinomas [20]. Neither did
Mosnier et al. in their study with 6 cases of gallbladder
adenocarcinomas [21]. However, Maitra et al. and Lugli et
al. reported positive rate 100% and 26% of Hep expression
in gallbladder adenocarcinomas, respectively [22, 23]. Our
results showed that Hep expression was detected in 45
(41.7%) out of 108 gallbladder adenocarnoma cases, which
is close to Lugli et al. reported 26% [23]. We found out the
expression rate of Hep in gallbladder adenocarcinoma
was significantly higher than those in peritumoral
tissues (23.9%) and chronic cholecystitis (5.7%). Hep
expression was positively associated with well-differentiated,
small size and no metastasis tumors. Most of positive
cases showed intestinal metaplasia., suggesting Hep
expression is associated with intestineal metaplasia. The
gallbladder lesions with Hep expression was significantly
correlated to early stage, small size, well differentiation,
and no-metastasis.
Highly consistency in CDX2 and Hep expression was
found in gallbladder adenocarcinoma. Unitivariate Kaplan-
Meier analysis and Multivariate Cox regression analysis
showed that increased expression of Hep also was an
Table 2 Multivariate cox regression analysis of overall survival in 67 patients with surgical resection of gallbladder carcinoma
Group Category B SE
(B)
Exp
(B)
P 95% CI for Exp(B)
Inferior Superior
Pathology type Adenoma canceration/well-/moderately-/
poorly-differentiatied/mucous carcinoma
0.508 0.378 1.66 0.253 0.79 3.49
Tumor Diameter <2.0 cm/≥2.0 cm 0.723 0.301 2.06 0.04 1.14 3.72
Lymphonode
metastasis
No/Yes 0.958 0.302 2.61 0.013 1.44 4.71
Surrounding tissue
invasion
No/Yes 0.911 0.308 2.49 0.027 1.36 4.55
CDX2 −/+ −0.852 0.350 0.43 0.014 0.21 0.84
Hep Par 1 −/+ −0.185 0.056 0.82 0.026 0.72 0.94
566 Q.-L. Li et al.independent better-prognostic factor. The result suggested
that some gallbladder adenocarcinoma expressed high
level of Hep, which might be related to intestinal
metaplasia of gallbladder epithelium, and Hep might be
one of the important biological markers reflecting the
prognosis of gallbladder adenocarcinoma. In addition,
highly consistency in CDX2 and Hep expression might
because that they were both biological markers of
intestinal metaplasia.
In summary, our findings indicate that expression of
CDX2 or Hep expression influenced the overall survival
in patients with gallbladder carcinoma. Both CDX2 and
Hep expression were independent markers of clinical
outcome in addition to lymph node metstasis and
surrounding tissue invasion in gallbladder adenocarcino-
ma patients, and might be useful to predict the prognosis
for gallbladder carcinoma.
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